Treatment of mild-to-moderate hypoglycemia in patients with type 1 diabetes treated with insulin pump therapy: are current recommendations effective?

被引:6
作者
Gingras, Veronique [1 ,2 ]
Desjardins, Katherine [1 ]
Smaoui, Mohamed Raef [2 ]
Savard, Valerie [1 ,2 ]
Messier, Virginie [1 ]
Haidar, Ahmad [3 ,4 ]
Legault, Laurent [5 ]
Rabasa-Lhoret, Remi [1 ,2 ,6 ,7 ]
机构
[1] IRCM, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada
[2] Univ Montreal, Dept Nutr, Montreal, PQ, Canada
[3] McGill Univ, Dept Biomed Engn, Montreal, PQ, Canada
[4] McGill Univ, Div Endocrinol, Montreal, PQ, Canada
[5] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada
[6] Univ Montreal, Ctr Hosp, Res Ctr, Montreal, PQ, Canada
[7] MDRC, Montreal, PQ, Canada
关键词
Hypoglycemia; Treatment; Carbohydrate; Continuous subcutaneous insulin infusion; Type; 1; diabetes; Insulin pump therapy; HORMONE ARTIFICIAL PANCREAS; ADULTS;
D O I
10.1007/s00592-017-1085-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mild-to-moderate hypoglycemia (blood glucose < 4.0 mmol/L) is recommended to be treated with 15 g of carbohydrates and to repeat the treatment if hypoglycemia persists after 15 min. This recommendation was established before intensive insulin therapy and based on studies using insulin with different pharmacokinetic profiles from actual insulin analogs showing that 15 g of glucose increases blood glucose by 1.5 mmol/L in 15 min. We aimed to explore the effect of current recommended treatment of mild-to-moderate hypoglycemia in type 1 diabetes (T1D) participants and factors associated with treatment effectiveness. This is a secondary analysis from three observational inpatient studies with a standardized and supervised treatment (16 g carbohydrates) of hypoglycemia (< 3.3 mmol/L with symptoms or < 3.0 mmol/L without symptom) in participants (47 adults-10 adolescents) with T1D using continuous subcutaneous insulin infusion ("insulin pumps"; CSII)). Twenty-seven participants presented a total of 48 hypoglycemia episodes treated by a single intake of 16 g of carbohydrates. Time required for normoglycemia recovery was 19.5 +/- 12.0 min. The rise in plasma glucose following treatment was 0.85 +/- 0.66 mmol/L in 15 min. Eighteen episodes (38%) were resolved (> 4.0 mmol/L) 15-min post-treatment. Glycemia at the time of treatment (< 3.2 mmol/L; p < 0.001) and a higher proportion of total daily insulin from basal doses (p = 0.03) were associated with a slower post-treatment plasma glucose rise. These results raise the possibility that sixteen grams of carbohydrates could be insufficient to treat a large proportion of hypoglycemia episodes in T1D patients treated with CSII. Factors affecting treatment effectiveness need to be investigated.
引用
收藏
页码:227 / 231
页数:5
相关论文
共 50 条
  • [41] A sensor augmented pump may improve awareness of hypoglycemia and quality of life in Japanese patients with type 1 diabetes mellitus
    Takagi, Satoshi
    Miura, Junnosuke
    Shimura, Kanako
    Hoshina, Sari
    Tsuchida, Yukiko
    Takita, Mikako
    Mochizuki, Shota
    Shen, Zhuo
    Asanuma, Takuya
    Takaike, Hiroko
    Babazono, Tetsuya
    DIABETOLOGY INTERNATIONAL, 2022, 13 (01) : 280 - 287
  • [42] Insulin Pump Therapy Improves Quality of Life of Young Patients With Type 1 Diabetes Enrolled in a Government-Funded Insulin Pump Program: A Qualitative Study
    Haynes, Emily
    Ley, Marissa
    Talbot, Pam
    Dunbar, Margaret
    Cummings, Elizabeth
    CANADIAN JOURNAL OF DIABETES, 2021, 45 (05) : 395 - 402
  • [43] Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment
    Escalada, F. Javier
    Halimi, Serge
    Senior, Peter A.
    Bonnemaire, Mireille
    Cali, Anna M. G.
    Melas-Melt, Lydie
    Karalliedde, Janaka
    Ritzel, Robert A.
    DIABETES OBESITY & METABOLISM, 2018, 20 (12) : 2860 - 2868
  • [44] Metabolic control and hypoglycaemia in people with type 1 diabetes: insulin pump therapy vs. intensified insulin therapy in an unselected cohort in routine care
    Kramer, Guido
    Kloos, Christof
    Mueller, Ulrich A.
    Wolf, Gunter
    Kuniss, Nadine
    DIABETOLOGY & METABOLIC SYNDROME, 2021, 13 (01)
  • [45] Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries
    Haluzik, Martin
    Kretowski, Adam
    Strojek, Krzysztof
    Czupryniak, Leszek
    Janez, Andrej
    Kempler, Peter
    Andel, Michal
    Tankova, Tsvetalina
    Boyanov, Mihail
    Duvnjak, Lea Smircic
    Madacsy, Laszlo
    Tarnowska, Iwona
    Zychma, Marcin
    Lalic, Nebojsa
    DIABETES THERAPY, 2018, 9 (02) : 727 - 741
  • [46] Retrospective Analysis and Patient Satisfaction Assessment of Insulin Pump Therapy in Patients with Type 2 Diabetes
    Gentry, Chad K.
    Cross, L. Brian
    Gross, Benjamin N.
    McFarland, M. Shawn
    Bestermann, William H.
    SOUTHERN MEDICAL JOURNAL, 2011, 104 (01) : 24 - 28
  • [47] Selected aspects of diabetes care among patients with type 2 diabetes treated with oral therapy, qualified to insulin therapy and treated with insulin
    Dudzinska, Marta
    Tarach, Jerzy S.
    Kurowska, Maria
    Malicka, Joanna
    Zwolak, Agnieszka
    Nowakowski, Andrzej
    FAMILY MEDICINE AND PRIMARY CARE REVIEW, 2013, 15 (02) : 95 - 97
  • [48] Insulin therapy and lipoproteins in patients with type 1 diabetes
    Cieluch, Aleksandra
    Uruska, Aleksandra
    Grzelka, Agata
    Zozulinska-Ziolkiewicz, Dorota
    CLINICAL DIABETOLOGY, 2016, 5 (04): : 111 - 116
  • [49] Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors
    Zhang, Tingting
    Ji, Linong
    Gao, Yan
    Zhang, Puhong
    Zhu, Dongshan
    Li, Xian
    Ji, Jiachao
    Zhao, Fang
    Zhang, Heng
    Guo, Xiaohui
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (11) : 675 - 684
  • [50] Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey
    Roze, Stephane
    Smith-Palmer, Jayne
    de Portu, Simona
    Saltik, A. Zeynep Ozdemir
    Akgul, Tugba
    Deyneli, Oguzhan
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (12) : 727 - 735